Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
出版年份 2019 全文链接
标题
Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
作者
关键词
Diabetes mellitus, SGLT2 inhibitor, Body composition monitor, Bioimpedance sprectroscopy, Fluid status, Overhydration, Renin–angiotensin–aldosterone system
出版物
Cardiovascular Diabetology
Volume 18, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-04-05
DOI
10.1186/s12933-019-0852-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
- (2019) Stuart J. McGurnaghan et al. DIABETOLOGIA
- Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2019) Tamara Milder et al. Journal of Clinical Medicine
- Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
- (2019) Tuba M. Ansary et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- The effect of dapagliflozin treatment on epicardial adipose tissue volume
- (2018) Takao Sato et al. Cardiovascular Diabetology
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
- (2018) Man Guo et al. DIABETES OBESITY & METABOLISM
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)
- (2018) Hiroki Nakajima et al. Diabetology & Metabolic Syndrome
- Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
- (2018) P. C. Lee et al. Obesity Reviews
- Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume and patient safety
- (2018) Elisabeth Schwaiger et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Effects of the SGLT2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan
- (2018) Ken Ohara et al. NEPHROLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Stroke in Type 2 Diabetes Mellitus
- (2018) Zien Zhou et al. STROKE
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
- (2017) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
- (2017) Takuo Yoshimoto et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
- (2016) Hiroyuki Tanaka et al. ADVANCES IN THERAPY
- Association of Plasminuria with Overhydration in Patients with CKD
- (2016) A. Schork et al. Clinical Journal of the American Society of Nephrology
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy
- (2016) Chiho Yamamoto et al. ENDOCRINE JOURNAL
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
- (2016) Konstantinos P Imprialos et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
- (2016) Harindra Rajasekeran et al. KIDNEY INTERNATIONAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
- (2016) Lawrence Blonde et al. POSTGRADUATE MEDICINE
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease
- (2015) Konstantinos P. Imprialos et al. JOURNAL OF HYPERTENSION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
- (2015) Ian J. Neeland et al. Diabetes Therapy
- Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
- (2015) Ian J. Neeland et al. Diabetes Therapy
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT
- (2014) Efrain Reisin et al. JOURNAL OF HYPERTENSION
- Bioimpedance-Guided Fluid Management in Hemodialysis Patients
- (2013) U. Moissl et al. Clinical Journal of the American Society of Nephrology
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
- (2009) Harold Bays CURRENT MEDICAL RESEARCH AND OPINION
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started